Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310331490> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4310331490 abstract "Scanty data on the anti- SARS-CoV-2 IgG level decay after two-dose BNT162b2 vaccination have been published in patients with psoriatic arthritis (PsA) on TNF inhibitors (TNFi). Similarly, no reports on the immunogenicity of a booster dose in such patients have been provided yet.We aimed to investigate the IgG level decay after two-dose BNT162b2 vaccination and the immunogenicity and safety of the booster dose in PsA patients on TNFi.Forty patients with classified PsA on TNFi undergoing booster dose with the BNT162b2 mRNA SARS- CoV-2 vaccine (BioNTech/Pfizer) were enrolled. Fifteen days after the third shot, serum IgG levels against SARS-CoV-2 (Abbott®ARCHITECT i2000SR, positivity cut-off 50 AU/mL) were assayed in all patients. Clinimetrics and treatment data were gathered. TNFi treatment was not discontinued. Sera from healthcare professionals were considered as healthy controls for 1:1 propensity score-matching. Student's t-test and logistic regression were used for investigating differences in immunogenicity between groups and predictors of antibody response.Even though the decay of IgG levels showed similar magnitude between groups, PsA patients had a lower IgG level than matched controls at 4 months after two-dose vaccination (2009.22±4050.22 vs. 6206.59±4968.33 AU/mL, respectively p=0.0006). Booster dose restored IgG levels to a similar extent in both groups (15846.47±12876.48 vs. 20374.46±12797.08 AU/ml p=0.20, respectively). Clinical Disease Activity Index (CDAI) did not change before and after vaccination (6.68±4.38 vs. 4.95±4.20, p=0.19).A BNT162b2 booster dose should be recommended in PsA patients on TNFi as its administration restores anti-SARS-CoV-2 IgG levels similar to healthy individuals." @default.
- W4310331490 created "2022-12-08" @default.
- W4310331490 creator A5011702168 @default.
- W4310331490 creator A5015866814 @default.
- W4310331490 creator A5017826737 @default.
- W4310331490 creator A5022870457 @default.
- W4310331490 creator A5037246836 @default.
- W4310331490 creator A5037774461 @default.
- W4310331490 creator A5063804101 @default.
- W4310331490 creator A5088023314 @default.
- W4310331490 date "2022-02-24" @default.
- W4310331490 modified "2023-10-14" @default.
- W4310331490 title "Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors" @default.
- W4310331490 doi "https://doi.org/10.55563/clinexprheumatol/hptln9" @default.
- W4310331490 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36441661" @default.
- W4310331490 hasPublicationYear "2022" @default.
- W4310331490 type Work @default.
- W4310331490 citedByCount "5" @default.
- W4310331490 countsByYear W43103314902023 @default.
- W4310331490 crossrefType "journal-article" @default.
- W4310331490 hasAuthorship W4310331490A5011702168 @default.
- W4310331490 hasAuthorship W4310331490A5015866814 @default.
- W4310331490 hasAuthorship W4310331490A5017826737 @default.
- W4310331490 hasAuthorship W4310331490A5022870457 @default.
- W4310331490 hasAuthorship W4310331490A5037246836 @default.
- W4310331490 hasAuthorship W4310331490A5037774461 @default.
- W4310331490 hasAuthorship W4310331490A5063804101 @default.
- W4310331490 hasAuthorship W4310331490A5088023314 @default.
- W4310331490 hasBestOaLocation W43103314901 @default.
- W4310331490 hasConcept C121332964 @default.
- W4310331490 hasConcept C12590561 @default.
- W4310331490 hasConcept C126322002 @default.
- W4310331490 hasConcept C1276947 @default.
- W4310331490 hasConcept C159654299 @default.
- W4310331490 hasConcept C203014093 @default.
- W4310331490 hasConcept C203165030 @default.
- W4310331490 hasConcept C22070199 @default.
- W4310331490 hasConcept C2776260265 @default.
- W4310331490 hasConcept C2777077863 @default.
- W4310331490 hasConcept C2780868878 @default.
- W4310331490 hasConcept C32611913 @default.
- W4310331490 hasConcept C71924100 @default.
- W4310331490 hasConceptScore W4310331490C121332964 @default.
- W4310331490 hasConceptScore W4310331490C12590561 @default.
- W4310331490 hasConceptScore W4310331490C126322002 @default.
- W4310331490 hasConceptScore W4310331490C1276947 @default.
- W4310331490 hasConceptScore W4310331490C159654299 @default.
- W4310331490 hasConceptScore W4310331490C203014093 @default.
- W4310331490 hasConceptScore W4310331490C203165030 @default.
- W4310331490 hasConceptScore W4310331490C22070199 @default.
- W4310331490 hasConceptScore W4310331490C2776260265 @default.
- W4310331490 hasConceptScore W4310331490C2777077863 @default.
- W4310331490 hasConceptScore W4310331490C2780868878 @default.
- W4310331490 hasConceptScore W4310331490C32611913 @default.
- W4310331490 hasConceptScore W4310331490C71924100 @default.
- W4310331490 hasLocation W43103314901 @default.
- W4310331490 hasLocation W43103314902 @default.
- W4310331490 hasOpenAccess W4310331490 @default.
- W4310331490 hasPrimaryLocation W43103314901 @default.
- W4310331490 hasRelatedWork W1968915527 @default.
- W4310331490 hasRelatedWork W4200165852 @default.
- W4310331490 hasRelatedWork W4205405760 @default.
- W4310331490 hasRelatedWork W4221113218 @default.
- W4310331490 hasRelatedWork W4224213282 @default.
- W4310331490 hasRelatedWork W4224255602 @default.
- W4310331490 hasRelatedWork W4283464416 @default.
- W4310331490 hasRelatedWork W4304784005 @default.
- W4310331490 hasRelatedWork W4310594073 @default.
- W4310331490 hasRelatedWork W4310659751 @default.
- W4310331490 isParatext "false" @default.
- W4310331490 isRetracted "false" @default.
- W4310331490 workType "article" @default.